• Journal of Radiation Protection and Research
• /
• 제22권1호
• /
• pp.47-58
• /
• 1997

MCNP4A 코드를 이용하여 MIRD 인형팬텀의 정면과 후방에서 입사하는 넓고 평행한 감마선빔에 대한 단위 공기커마당 유효선량 환산계수와 단위 플르언스당 장기의 등가선량을 계산하였다. 본 연구에서 고려한 감마선은 0.03-10 MeV 에너지 구간에서 20개의 단일에너지에 대해 수행되었다. 환산계수의 계산결과를 ICRP/ICRU의 연구결과 발표예정 출판물에 주어진 해당되는 값과 비교한 결과 편차 10%이내에서 일치하고 있다. 결과의 차이가 발생한 이유는 MIRD 팬텀과 ADAM/EVE 팬텀의 기하학적 차이가 주원인이며 또한 계산에 사용된 전산코드와 단면적 차이 등으로 판단된다. 특정 식도 모델을 사용한 결과로부터 얻어진 유효선량과 흉선과 췌장에 대한 등가선량을 채택함으로써 얻어지는 유효선량은 약간(최고 5%)의 차이를 보인다. 기타장기로부터 상부대장을 제외했을 때 본 연구에서 다루었던 감마선 선량학적 측면의 경우에서는 중요하지 않은 것으로 나타났다.

• 대한방사선기술학회지:방사선기술과학
• /
• 제43권6호
• /
• pp.443-451
• /
• 2020

This study is to evaluate absorbed dose from right lung for brachytherapy and to estimate the effects of tissue heterogeneities on dose distribution for Iridium-192 source using Monte Carlo simulation. The study employed Geant4 code as Monte Carlo simulation to calculate the dosimetry parameters. The dose distribution of Iridium-192 source in solid water equivalent phantom including aluminium plate or steel plate inserted was calculated and compared with the measured dose by the ion chamber at various distances. And the simulation was used to evaluate the dose of gamma radiation absorbed in the lung organ and other organs around it. The dose distribution embedded in right lung was calculated due to the presence of heart, thymus, spine, stomach as well as left lung. The geometry of the human body was made up of adult male MIRD type of the computational human phantom. The dosimetric characteristics obtained for aluminium plate inserted were in good agreement with experimental results within 4%. The simulation results of steel plate inserted agreed well with a maximum difference 2.75%. Target organ considered to receive a dose of 100%, the surrounding organs were left the left lung of 3.93%, heart of 10.04%, thymus of 11.19%, spine of 12.64% and stomach of 0.95%. When the statistical error is performed for the computational human phantom, the statistical error of value is under 1%.

• 대한방사선기술학회지:방사선기술과학
• /
• 제46권6호
• /
• pp.501-508
• /
• 2023

This study used a adult absorption dose phantom (CIRS model 701-G, USA) made of human equivalent material and the vascular imaging equipment Allura Xper FD 20 (Philips, Netherlands). Optically stimulated luminescent dosimeters (OSLD) were inserted into the anatomical positions corresponding to each organ, and the exposure dose was measured. Dose area product (DAP) and air kerma (AK) measured by the dose meter in the equipment were compared. Continuous imaging was performed at two angles for a total of 20 minutes, with a frame per seconds of 3.75 and 7.5 fps and an FOV of 42 cm, 37 cm, and 31 cm, respectively, under the conditions of fluoflavor I, II, and III, each selected for 5 repetitions. This study was found that selecting a lower fps was the most effective way to reduce patient exposure dose, and adjusting the fluoflavor was a good alternative method for reducing patient exposure dose at high fps. Therefore the method of condition change with the greatest dose reduction effect is to set the minimum FPS and can reduce patient exposure dose according to geometric conditions and fluoflavor characteristics.

• 대한방사선치료학회지
• /
• 제27권1호
• /
• pp.87-95
• /
• 2015

목 적 : 안와 주변 방사선 치료 시 수정체 피폭선량감소를 위하여 사용된 2차 차폐 block의 유용성을 알아보고자 한다. 대상 및 방법 : Human phantom(Alderson Rando Phantom, The Phantom Laboratory, USA)을 사용하여 CT(Somatom Definition AS, Siemens, Germany) 모의촬영 후 전산화치료계획시스템(Pinnacle, PHILIPS, USA)을 통해 실제 치료와 유사한 IMRT치료계획을 실시하였다. 2차 차폐를 위하여 두께 3mm 지름 25 mm의 납판과 3 mm tungsten eye-shield block(Extra small size, Radiation Products Design, Inc, USA)를 사용하였으며, TPS(Treatment Planning System) 상의 lens dose와 모의치료 상의 lens dose를 OSLD로 측정 비교하였다. 또한, 5 cm 두께의 acrylic phantom에 동일한 조건의 2차 차폐물인 3 mm 납판과 tungsten eye-shield block을 사용하여 200 MU(6 MV, SPD(Source to Phantom Distance)=100 cm, $F{\cdot}S\;5{\times}5cm$)를 조사 및 측정하였으며, 조사야 밖의 누설선 및 투과방사선 영향을 제한시키고자 8 cm 납블럭(O.S.B: Outside Scatter Block)을 적용하여 위와 동일한 실험을 시행하였다. 조사야로부터 1 cm 이격하여 phantom 끝 옆면에 OSLD(Optically Stimulated Luminescence Dosimeter)를 부착하였고, eyelid의 두께에 해당하는 bolus 3 mm를 적용하였다. 결 과 : human phantom을 이용하여 IMRT 치료계획 상의 Lens dose와 실 측정치는 각각 315.9, 216.7 cGy가 측정되었고, 3 mm 납판과 tungsten eye-shield block으로 2차 차폐 후 각각 234.3, 224.1 cGy가 측정되었다. acrylic phantom을 이용한 실험 결과는 no block, 3 mm 납판, tungsten eye-shield block을 사용했을 때 5.24, 5.42, 5.39 cGy가 측정되었으며, 조사야 밖에 O.S.B를 적용하여 no block, 3 mm 납판, tungsten eye-shield block을 실험한 결과 각각 1.79, 2.00, 2.02 cGy가 측정되었다. 결 론 : 광자선 조사 시 critical organ을 보호하기 위하여 2차 차폐를 적용할 시에는 field 외부일지라도 헤드 누설방사선 및 collimator & MLC 투과방사선이 존재하므로 치료부위와 beam 방향에 따라 금속과 같은 높은 원자번호의 차폐물질이 critical organ근처에 있다면 선량 증가의 원인이 될 수 있다는 사실을 알 수 있었다. 따라서 피폭선량 감소를 위한 2차 차폐의 시도는 분명 의미가 있었으나 미 검증된 시도는 오히려 역효과를 가져올 수 있다는 사실을 인지하여 QA를 통해 목적에 부합하는 결과가 나오는지를 사전에 알아보아야 할 것이다.

• Journal of Radiation Protection and Research
• /
• 제26권3호
• /
• pp.291-298
• /
• 2001

The designed release rate of liquid effluents from radwaste treatment system should be calculated and evaluated during normal operation, including anticipated operational occurrence and be assured that the release concentration and off-site dose at unrestricted area do not exceed the limits of regulation. The expected annual release rate and off-site dose for the currently operating nuclear power plants in Korea had been calculated and evaluated using PWR-GALE and LADTAP-II which was based on USNRC Regulatory Guide 1.109. Recently, the MOST Notice 2001-2 related to release concentration and off-site dose at unrestricted area was revised to reflect the concept of ICRP-60. It is necessary for KORI 3&4 to re-calculate the release concentration and off-site dose and to compare these results with the limits of regulation. As the results of assessment, we confirmed that the release concentrations were less than its limits of MOST Notice 2001-2 and the off-site dose at unrestricted area using K-DOSE60 was 3.61E-03 mSv/yr to the age of five for the effective dose, and 4.10E-2 mSv/yr to thyroid of the age of five for the organ equivalent dose. We also confirmed the off-site dose was within the limits of MOST Notice 2001-2. Therefore, the release concentration and off-site dose re-evaluated at unrestricted area in KORI 3&4 were well below the regulation limits of MOST Notice 2001-2.

• 대한본초학회지
• /
• 제32권4호
• /
• pp.33-38
• /
• 2017

Objectives : Termitomyces albuminosus (Berk.) Heim is one of the famous wild edible mushrooms in the southern part of China. It is known that Termitomyces albuminosus, like Aconitum koreanum used in Korean traditional medicine, contains a kind of cerebroside, termitomycesphin, causing a pharmacologic effect on the neuron system. The pharmacologic effect of Termitomyces albuminosus can be used to possibly replace Aconitum koreanum. However, It needs to be certified as safe before it can be used. Here, a single-oral toxicity test and safety classification was conducted to obtain acute information of the toxicity of dried-Termitomyces albuminosus powder and to secure its safety in clinical applications. Methods : In order to calculate approximate lethal dose(ALD), test substance was orally administered to male and female SD-rat at dose levels of 5,000 and 0 (vehicle control) mg/kg (body weight). Based on the result of this toxicity, also the estimation of safety classification was calculated using the HED-based (human equivalent dose) MOS (margin of safety). Results : There were no mortalities, test substances treatment-related clinical signs, no changes in the body or organ weights, and no gross or histopathological findings at 14 days after treatment with test substance. Thus, the approximate lethal dose of dried-Termitomyces albuminosus powder was considered over 5,000 mg/kg in both female and male mice. Conclusions : Based on the limit dose, 5000 mg/kg, it was estimated that dried-Termitomyces albuminosus powder is classified as "Specified class B" indicating that clinical dose is not limited to patients as safe as food.

• 대한본초학회지
• /
• 제33권4호
• /
• pp.53-58
• /
• 2018

Objectives : Kaempferia parviflora Rhizome is black ginger indigenous to Laos and Thailand. It has been used as a folk medicine to improve blood flow and promote vitality and longevity with good health and well being. For these reasons, Kaempferia parviflora Rhizome has been focused on developing it as a food or food supplement. In addition, Kaempferia parviflora Rhizome could be under consideration of new prescription based on its characteristic compounds, polymethoxyflavonoids. However, it needs to be certified as safe before it can be used. Here, a single-oral toxicity test and safety classification was carried out to identity acute information of the toxicity of Kaempferia parviflora Rhizome powder and to make sure of its safety in clinical applications. Methods : Test substance was orally administered to male and female SD-rat at dose levels of 5000 mg/kg to estimate approximate lethal dose(ALD). Based on the acute information of the toxicity, the safety classification was estimated using the HED(human equivalent dose)-based MOS(margin of safety). Results : At 14 days after treatment with test substance. there were no of test substance related with mortalities and clinical signs. In addition, no changes in the body or organ weights and no gross or histopathological findings were observed. Thus, the ALD of Kaempferia parviflora Rhizome powder was considered over 5,000 mg/kg in both female and male mice. Conclusions : Based on the single oral toxicity test using the highest and limit dose, 5,000 mg/kg and the decision guideline for safety classification based on HED-based MOS, it was estimated that Kaempferia parviflora Rhizome powder is classified as "Specified class B" indicating that clinical dose is not limited to patients as safe as food.

• 대한방사선치료학회지
• /
• 제26권2호
• /
• pp.337-343
• /
• 2014

목 적 : 최근 시행되고 있는 가임기 여성의 유방암 토모치료 시 치료영역 외에서 발생되는 산란 및 누설에 의한 난소산란선량을 측정하여 평가하고자 한다. 대상 및 방법 : 인체모형팬텀(Aldorson Rando phantom, USA)을 대상으로 전산화단층영상 2.5 mm 획득 후, Tomotherapy Planning station(Tomotherapy, Inc, USA)을 이용하여 좌측 유방암 환자의 토모테라피 치료계획(Tomotherapy Helical & Tomotherapy Direct)을 수립하였다. 난소의 산량 선량 측정을 위한 측정 지점은 치료계획면적의 30 cm 아래 떨어진 골반의 좌우 위치로 직경 1.5 mm, 길이가 12mm인 저에너지용 보상필터가 들어있는 종류의 유리선량계 (GD-352M, ASAHI TECHNO GLASS CO, Japan)를 이용하여 각 5회씩 측정하여 평균하였으며, 선형지수-선량반응모델을 이용한 장기등가선량(organ equivalent dose: OED)으로 평가하였다. 결 과 : 토모 Helical 및 토모 Direct의 두 가지 방식으로 측정된 난소의 산란선량은 좌측 난소부위가 각각 평균 $64.94{\pm}0.84mGy$, $37.64{\pm}1.20mGy$이고, 우측 난소부위가 평균 $64.38{\pm}1.85mGy$, $32.96{\pm}1.11mGy$로 나타났다. 이는 토모치료 시 비교적 모니터 단위(MU)가 크고 조사 시간이 긴 토모Helical 방식이 토모Direct에 비하여 측정된 산란선량의 양이 보다 약 1.8배 높은 경향을 보였다. 결 론 : 가임기 여성의 유방암 토모테라피 시 발생하는 좌우측 난소의 산량선량은 ICRP 권고 선량이하로, 불임 및 2차 암 발생에 대한 우려 수준은 현저히 낮지만 향후 유방암 발생 연령층이 낮아지고, 토모테라피와 같이 고정밀 영상유도장치를 이용한 방사선치료가 발달할수록, 가임기 여성 환자의 난소산란선량에 대한 임상적 추적조사가 더욱 필요할 것으로 사료된다.

• 한국방사선학회논문지
• /
• 제7권2호
• /
• pp.121-129
• /
• 2013

최근 다중검출기 CT의 보편화 된 사용으로 환자의 피폭선량이 증가하고 있다. 따라서 광자극발광선량계를 이용해 촬영 목적 부위와 주변 결정장기에 대한 환자의 피폭선량을 측정하고 그에 따른 생물학적 효과를 예측하여 저감화 방안을 제시하고자 하였다. ICRP에서 권고한 표준안을 대상으로 만들어진 인체 모형 표준 팬텀에 교정상수를 부여받은 OSD 선량계를 측정하고자 하는 좌 우 수정체, 갑상선, 촬영의 중심점, 생식선에 부착하여 각 검사 부위별 노출 조건과 동일한 상태에서 환자의 피폭 선량을 모사하였다. OSL 선량계의 평균 교정상수는 $1.0058{\pm}0.0074$이었으며 검사 부위별 주변 결정장기의 등가선량은 좌 우측 수정체의 경우 직접 피폭이 약 50mGy로 최대였으며 간접 피폭되는 경우 0.24mGy, 원거리에서는 0.005mGy미만의 기준 준위 이하로 측정되었다. 갑상선의 경우 두부 검사에서 10.89mGy로 최대였으며 흉부에서 7.75mGy, 복부 및 요추부, 골반부에서는 기준 미만이었다. 생식선의 경우 골반검사에서 21.98mGy로 최대였으며 간접 피폭되는 검사에서 기준 준위 미만에서 6.92mGy까지 피폭되었다. CT 검사에서 DRL에 대한 저감화 방법은 국제기구에서 권고하고 있는 방사선 방어 원칙에 대한 정당한 해석과 제도적 뒷받침이 필요하다. 따라서 환자의 피폭을 최소화하기 위해서는 정당성을 충족하여야 하며 환자의 피폭선량에 미치는 영향들을 체계화하고 조직의 불필요한 피폭을 최소화 하여야 한다.

• 한국의학물리학회지:의학물리
• /
• 제29권4호
• /
• pp.143-149
• /
• 2018

To verify the correlations between the clinical outcomes and physical factors of short-course chemoradiotherapy (SCRT) and long-course chemoradiotherapy (LCRT) with delayed surgery in patients with rectal cancer. Seventy-two patients with rectal cancer were enrolled in this study. Nineteen patients were treated with SCRT (25 Gy, 5 fractions) by intensity-modulated radiation therapy (IMRT), and 53 patients were treated with LCRT (50.4 Gy, 28 fractions) by three-dimensional conformal radiation therapy (3DCRT). Various physical factors for the target and organs at risk (OARs) were calculated to compare the clinical outcomes. The organ equivalent dose (OED) and lifetime attributable risk (LAR) of bowels and bladders were similar between the SCRT and LCRT groups, whereas the values of femurs were higher in the LCRT group. The equivalent uniform dose and normal tissue complication probability were higher in the LCRT than the SCRT group for most organs. Treatment complications, including anastomotic leakage, bowel adhesion, and hematologic toxicity, were not significantly different between SCRT and LCRT groups. CIs were $0.84{\pm}0.2$ and $0.61{\pm}0.1$ for SCRT and LCRT, respectively. The CVIs were $1.07{\pm}0.0$ and $1.10{\pm}0.1$, and the HIs were $0.09{\pm}0.0$ and $0.11{\pm}0.1$ for SCRT and LCRT, respectively. The sphincter-saving rates were 89.5% and 94.3% for SCRT and LCRT, respectively. The complete pathologic remission rates were 21.1% and 13.2%, and the down-staging rates were 47.4% and 26.4% for SCRT and LCRT, respectively. SCRT with IMRT is comparable to conventional LCRT in both physical indexes and clinical outcome. The preoperative SCRT, compensated by IMRT, is an effective and safe modality.